Safety Study of Ch-mAb7F9 for Methamphetamine Abuse

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2012
The primary objective is to determine the safety and tolerability of single, ascending intravenous doses of ch-mAb7F9 in healthy subjects via physical examinations and adverse event, vital sign, electrocardiogram (ECG), and clinical laboratory testing.Phase 1a, randomized, placebo-controlled, first-in-human (FIH) study of intravenously administered ch-mAb7F9. The study will be a double-blind, dose-escalation study. Each subject will receive a single dose of ch-mAb7F9 or placebo (saline).
Epistemonikos ID: a224292275e1a1672703d952e0447dbeee5bdffd
First added on: May 11, 2024